As post-treatment resistant cancer cells show activation of the ERBB signaling pathway, we took a parallel experimental approach to test whether endocrine and CDK4/6i treatments drive compensatory ERBB receptor expression in vitro. This evidence concerns the gene EGFR and cancer.